Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.88 USD | +1.95% | +1.73% | -46.34% |
Apr. 16 | HC Wainwright Adjusts Microbot Medical's Price Target to $7 From $8, Keeps Buy Rating | MT |
Mar. 27 | Microbot Medical Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Capitalization 1 | 73.08 | 48.98 | 53.31 | 23.75 | 19.2 | 12.67 |
Enterprise Value (EV) 1 | 73.08 | 48.98 | 53.31 | 23.75 | 19.2 | 12.67 |
P/E ratio | - | - | - | - | - | - |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 7,186 | 7,108 | 7,108 | 7,891 | 11,707 | 14,399 |
Reference price 2 | 10.17 | 6.890 | 7.500 | 3.010 | 1.640 | 0.8800 |
Announcement Date | 4/14/20 | 3/31/21 | 3/31/22 | 3/31/23 | 3/27/24 | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - |
EBIT 1 | -7.24 | -9.089 | -11.36 | -13.28 | -9.855 | -9 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - | - |
Net income | - | - | - | - | - | - |
Net margin | - | - | - | - | - | - |
EPS | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 4/14/20 | 3/31/21 | 3/31/22 | 3/31/23 | 3/27/24 | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -2.552 | -3.937 | -3.176 | -3.563 | -3.474 | -3.068 | -2.919 | -2.324 | -2.544 | -2.068 | -2.25 | -2.25 | -2.25 | -2.25 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net income | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/15/21 | 3/31/22 | 5/16/22 | 8/15/22 | 11/14/22 | 3/31/23 | 5/17/23 | 8/14/23 | 11/14/23 | 3/27/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 4/14/20 | 3/31/21 | 3/31/22 | 3/31/23 | 3/27/24 | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-46.34% | 12.67M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- MBOT Stock
- Financials Microbot Medical Inc.